JP2017500567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500567A5 JP2017500567A5 JP2016541152A JP2016541152A JP2017500567A5 JP 2017500567 A5 JP2017500567 A5 JP 2017500567A5 JP 2016541152 A JP2016541152 A JP 2016541152A JP 2016541152 A JP2016541152 A JP 2016541152A JP 2017500567 A5 JP2017500567 A5 JP 2017500567A5
- Authority
- JP
- Japan
- Prior art keywords
- levels
- acid
- biomarker
- level
- dnl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 34
- 239000000090 biomarker Substances 0.000 claims 26
- 150000002632 lipids Chemical class 0.000 claims 21
- 230000004132 lipogenesis Effects 0.000 claims 16
- 102100022882 Deoxyribonuclease-2-alpha Human genes 0.000 claims 15
- 101000902850 Homo sapiens Deoxyribonuclease-2-alpha Proteins 0.000 claims 15
- 235000014113 dietary fatty acids Nutrition 0.000 claims 14
- 229930195729 fatty acid Natural products 0.000 claims 14
- 239000000194 fatty acid Substances 0.000 claims 14
- 150000004665 fatty acids Chemical class 0.000 claims 14
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 12
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 12
- 229940031439 squalene Drugs 0.000 claims 12
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 12
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 11
- 239000008280 blood Substances 0.000 claims 8
- 210000004369 blood Anatomy 0.000 claims 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 8
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 claims 6
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 claims 6
- 229940049918 linoleate Drugs 0.000 claims 6
- -1 lipid classes of myristic acid Chemical class 0.000 claims 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 5
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 5
- 210000002374 sebum Anatomy 0.000 claims 5
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims 4
- 206010067125 Liver injury Diseases 0.000 claims 4
- 235000021360 Myristic acid Nutrition 0.000 claims 4
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003550 marker Substances 0.000 claims 4
- 238000005259 measurement Methods 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 claims 3
- 239000012491 analyte Substances 0.000 claims 3
- 238000013178 mathematical model Methods 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims 2
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 2
- 108010018763 Biotin carboxylase Proteins 0.000 claims 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 claims 2
- 108010087894 Fatty acid desaturases Proteins 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 102000016553 Stearoyl-CoA Desaturase Human genes 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 210000002615 epidermis Anatomy 0.000 claims 2
- 231100000234 hepatic damage Toxicity 0.000 claims 2
- 231100000753 hepatic injury Toxicity 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 230000008818 liver damage Effects 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 claims 2
- 150000008105 phosphatidylcholines Chemical class 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000004927 skin cell Anatomy 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- 102000057234 Acyl transferases Human genes 0.000 claims 1
- 108700016155 Acyl transferases Proteins 0.000 claims 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 claims 1
- 101100011517 Drosophila melanogaster ELOVL gene Proteins 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 101000863721 Homo sapiens Deoxyribonuclease-1 Proteins 0.000 claims 1
- 150000001982 diacylglycerols Chemical class 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- CNVZJPUDSLNTQU-OUKQBFOZSA-N petroselaidic acid Chemical compound CCCCCCCCCCC\C=C\CCCCC(O)=O CNVZJPUDSLNTQU-OUKQBFOZSA-N 0.000 claims 1
- NNNVXFKZMRGJPM-KHPPLWFESA-N sapienic acid Chemical compound CCCCCCCCC\C=C/CCCCC(O)=O NNNVXFKZMRGJPM-KHPPLWFESA-N 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 238000013179 statistical model Methods 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361918866P | 2013-12-20 | 2013-12-20 | |
| US61/918,866 | 2013-12-20 | ||
| US201461934033P | 2014-01-31 | 2014-01-31 | |
| US61/934,033 | 2014-01-31 | ||
| PCT/US2014/071035 WO2015095451A1 (en) | 2013-12-20 | 2014-12-18 | Biomakers of de novo lipogenesis and methods using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500567A JP2017500567A (ja) | 2017-01-05 |
| JP2017500567A5 true JP2017500567A5 (enExample) | 2018-02-01 |
| JP6557235B2 JP6557235B2 (ja) | 2019-08-07 |
Family
ID=53403674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016541152A Active JP6557235B2 (ja) | 2013-12-20 | 2014-12-18 | ｄｅ ｎｏｖｏ脂質生成のバイオマーカーおよびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160356798A1 (enExample) |
| EP (1) | EP3082833B1 (enExample) |
| JP (1) | JP6557235B2 (enExample) |
| AU (1) | AU2014364539B2 (enExample) |
| CA (1) | CA2933571A1 (enExample) |
| ES (1) | ES2708807T3 (enExample) |
| MX (1) | MX2016008045A (enExample) |
| SG (1) | SG11201604702YA (enExample) |
| WO (1) | WO2015095451A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105400732A (zh) * | 2015-11-19 | 2016-03-16 | 南京理工大学 | 一种酒精性脂肪肝斑马鱼模型的构建方法 |
| JP6992057B2 (ja) | 2016-06-10 | 2022-01-13 | クラリティ コスメティックス インコーポレイテッド | 非面皰形成性の毛髪および頭皮ケア製剤ならびにその使用方法 |
| GB201614455D0 (en) | 2016-08-24 | 2016-10-05 | Univ Oxford Innovation Ltd | Biomarkers |
| US11709169B2 (en) * | 2017-02-07 | 2023-07-25 | National Jewish Health | Lipid abnormalities and association with atopic allergic diseases |
| EP3602605A4 (en) * | 2017-03-31 | 2020-12-30 | Metabolon, Inc. | FULL AND QUANTITATIVE ANALYSIS OF LIPIDS AND TOCOPHEROLS |
| US11642300B2 (en) | 2019-05-15 | 2023-05-09 | Johnson & Johnson Consumer Inc. | Method of selecting skin treatment regimens, ingredients and compositions |
| US20220142560A1 (en) | 2020-11-06 | 2022-05-12 | Johnson & Johnson Consumer Inc. | Microbiome and metobolome clusters to evaluate skin health |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1438420B1 (en) * | 2001-09-24 | 2009-09-16 | Lipomics Technologies, Inc. | Methods of using quantitative lipid metabolome data |
| JP4682980B2 (ja) * | 2004-04-23 | 2011-05-11 | 味の素株式会社 | 非アルコール性脂肪肝炎鑑別方法 |
| US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| CN102317786A (zh) * | 2007-04-18 | 2012-01-11 | 特提斯生物科学公司 | 糖尿病相关性生物学标记物及其使用方法 |
| WO2010028336A2 (en) * | 2008-09-08 | 2010-03-11 | President And Fellows Of Harvard College | Fatty acid c16:1n7-palmitoleate a lipokine and biomarker for metabolic status |
| WO2012040318A2 (en) * | 2010-09-23 | 2012-03-29 | University Of Miami | Compositions, methods and kits for detecting melanoma and margins of melanoma |
-
2014
- 2014-12-18 CA CA2933571A patent/CA2933571A1/en not_active Abandoned
- 2014-12-18 AU AU2014364539A patent/AU2014364539B2/en active Active
- 2014-12-18 WO PCT/US2014/071035 patent/WO2015095451A1/en not_active Ceased
- 2014-12-18 EP EP14870759.9A patent/EP3082833B1/en active Active
- 2014-12-18 JP JP2016541152A patent/JP6557235B2/ja active Active
- 2014-12-18 US US15/104,560 patent/US20160356798A1/en not_active Abandoned
- 2014-12-18 ES ES14870759T patent/ES2708807T3/es active Active
- 2014-12-18 MX MX2016008045A patent/MX2016008045A/es active IP Right Grant
- 2014-12-18 SG SG11201604702YA patent/SG11201604702YA/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500567A5 (enExample) | ||
| Hodson et al. | Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake | |
| Arora et al. | Non-invasive diagnosis of fibrosis in non-alcoholic fatty liver disease | |
| Ilias et al. | Adipose tissue lipolysis and circulating lipids in acute and subacute critical illness: effects of shock and treatment | |
| EP2579037A4 (en) | DEVICE FOR TESTING THE SERIOUSNESS OF A DISEASE | |
| EP2532748A3 (en) | DNA aptamer specifically binding to human cardiac troponin I | |
| JP6557235B2 (ja) | ｄｅ ｎｏｖｏ脂質生成のバイオマーカーおよびその使用方法 | |
| Horai et al. | Pathological characterization and morphometric analysis of hepatic lesions in SHRSP5/Dmcr, an experimental non‐alcoholic steatohepatitis model, induced by high‐fat and high‐cholesterol diet | |
| CN111370066A (zh) | 一种利用斑马鱼评估离子液体对脂代谢影响的方法 | |
| CN117665225A (zh) | 一种构建综合评价乌嘴白羽鸭肉品质的方法及综合评价的新方法 | |
| RU2009117008A (ru) | Способ диагностики бронхиальной астмы у детей раннего возраста с использованием данных цитологии индуцированной мокроты | |
| Hodson et al. | Micro-techniques for analysis of human adipose tissue fatty acid composition in dietary studies | |
| CN203732398U (zh) | 粪便粘度测定装置 | |
| Wang et al. | Effect of Increasing the Foot Area on the Load-Velocity Relationship of the Underwater Dolphin Kick | |
| Rosic et al. | Mathematical analysis of the heart rate performance curve during incremental exercise testing | |
| Blavy et al. | A minimal model for hepatic fatty acid balance during fasting: Application to PPAR alpha-deficient mice | |
| Kawasumi et al. | New criteria of hyperlipidemia with insulin resistance in dogs | |
| Biben et al. | Prevalence of Metabolic Syndrome Risk Factors in College-Aged Students | |
| So et al. | Irisin is associated with physical activity level and hepatic steatosis grade in non-alcoholic fatty liver disease subjects: 841 | |
| Vuppalanchi et al. | Is liver stiffness measurement (LSM) by Fibroscan better than FIB4 score for prediction of clinically significant fibrosis in patients with NAFLD?: 842 | |
| De Mello Costa et al. | Circulating angiotensin converting enzyme in endurance horses: effect of exercise on blood levels and its value in predicting performance | |
| Samoilova et al. | Features of the mobile pool of fatty acids (lipoproteins and free fatty acids) in adolescents with different body weights | |
| Cavallo et al. | 217 Distinctive and shared signatures of Th1 and Th2 cytokines on the lipid pathways involved in the epidermal barrier function | |
| Špoljarić et al. | Influence of Motor Skills and Morphological Characteristics on Success in Kayak | |
| Mohiee El Deen Abdel Aziz et al. | Evaluation of serum connective tissue growth factor [CTGF] as a new noninvasive marker for assessment of hepatic fibrogenesis in children with chronic liver diseases |